The combination of flavopiridol with imatinib showed enhanced efficacy against a MYB-expressing BCR/ABL1-positive CML zebrafish model as compared to imatinib monotherapy[181]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.